“With the acquisition of the BioSET portfolio, Ferring intends to build on its growing success in orthopaedics,” said Michel Pettigrew, president of the Ferring executive board and chief operating officer, “By developing new orthobiologic products for joint fusion, we will expand and diversify our offering to include innovative solutions for orthopaedic surgery.”
In addition to AMPLEX and PREFIX, Ferring has acquired a library of rationally designed biomimetic peptides intended for applications in bone and tissue repair.